This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and
contact information

Hematology

Myeloproliferative disorder

Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1; GLUT1)

In vitro and mouse studies suggest inhibiting GLUT1 could help prevent weight loss associated with myeloproliferative disorder. In a mouse model of myeloproliferative disorder, adipose tissue atrophy, glucose consumption by leukocytes and inflammation in bone marrow were greater than what was seen in control mice. In three mouse models of the disease, small hairpin RNA-mediated knockdown of Glut1 in the bone marrow decreased adipose tissue loss compared with no knockdown. Next steps could include identifying and testing GLUT1 inhibitors in animal models.

SciBX 6(5); doi:10.1038/scibx.2013.115
Published online Feb. 7, 2013

Patent and licensing status unavailable

Gautier, E.L. et al. J. Exp. Med.; published online Jan. 14, 2013;
doi:10.1084/jem.20121357
Contact: Laurent Yvan-Charvet, Columbia University, New York, N.Y.
e-mail:
ly2159@columbia.edu